article thumbnail

FDA’s Revised Draft Guidance on Biological Product Promotion Provides Additional Recommendations/Clarifications

FDA Law Blog: Biosimilars

This Revised Draft Guidance provides considerations for manufacturers, packers or distributors (dubbed “firms”) of prescription biological reference products, biosimilar products, and interchangeable biosimilar products presenting data and information about such products in promotional materials in a truthful and non-misleading way.

article thumbnail

Pipelinepharma marketplace records quadruple growth over a single year

Pharma Mirror

As a response to increasing demand, Pipelinepharma will introduce biosimilar drugs into a separate category. The post Pipelinepharma marketplace records quadruple growth over a single year appeared first on Pharma Mirror Magazine. We are building upon our vision to become the world’s leading B2B pharma product platform.

Dosage 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Arecor heads for London Stock Exchange with drug reformulation strategy

pharmaphorum

It builds on the company’s four partnership projects: two with the generics and biosimilars firm Hikma, one with US biotech Inhibrix and another with an unnamed biosimilars partner. Eli Lilly, Novo Nordisk and there’s a group of biosimilar companies who already have a footprint in diabetes.”

article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. They employed hundreds of new salespeople to detail doctors and hospitals, spent millions on TV and magazine ads and handed out masses of free samples. Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively.